ev3 Inc. Agrees to Settle Stockholder Litigation
July 06, 2010 17:15 ET
|
ev3 Inc.
PLYMOUTH, Minn., July 6, 2010 (GLOBE NEWSWIRE) -- ev3 Inc. (Nasdaq:EVVV), a global endovascular device company, today announced that it has reached an agreement with the plaintiffs to settle the...
ev3 Announces Acceptance of Pipeline(TM) Embolization Device
June 21, 2010 06:00 ET
|
ev3 Inc.
PLYMOUTH, Minn., June 21, 2010 (GLOBE NEWSWIRE) -- ev3 Inc. (Nasdaq:EVVV), a global endovascular device company, today announced that the U.S. Food and Drug Administration (FDA) formally accepted for...
ev3 Inc. Files PMA Application for FDA Approval of Pipeline Embolization Device
May 18, 2010 06:00 ET
|
ev3 Inc.
PLYMOUTH, Minn., May 18, 2010 (GLOBE NEWSWIRE) -- ev3 Inc. (Nasdaq:EVVV), a global endovascular device company, today announced that it has filed the final module of its Premarket Approval (PMA)...
ev3 to Present at the 2010 Citi Investment Research Global Health Care Conference on May 27, 2010
May 17, 2010 16:15 ET
|
ev3 Inc.
PLYMOUTH, Minn., May 17, 2010 (GLOBE NEWSWIRE) -- ev3 Inc. (Nasdaq:EVVV) today announced that Shawn McCormick, senior vice president and chief financial officer, is scheduled to present at the 2010...
ev3 to Present at Baird's 2010 Growth Stock Conference on May 19, 2010
May 10, 2010 16:15 ET
|
ev3 Inc.
PLYMOUTH, Minn., May 10, 2010 (GLOBE NEWSWIRE) -- ev3 Inc. (Nasdaq:EVVV) today announced that Robert Palmisano, president and chief executive officer, is scheduled to present at Baird's 2010 Growth...
ev3 to Present at the Bank of America Merrill Lynch Health Care Conference on May 11, 2010
May 04, 2010 16:15 ET
|
ev3 Inc.
PLYMOUTH, Minn., May 4, 2010 (GLOBE NEWSWIRE) -- ev3 Inc. (Nasdaq:EVVV) today announced that Robert Palmisano, president and chief executive officer, is scheduled to present at the Bank of America...
ev3 Reports 2010 First Quarter Financial Results
April 29, 2010 06:00 ET
|
ev3 Inc.
First Quarter Net Sales Increase 23% to $123.9 Million
First Quarter GAAP EPS Increases to $0.09
Cash and Cash Equivalents Increase to $116.8 Million
Full-Year 2010 Revenue and Earnings...
ev3 Inc. Announces Completion of Patient Enrollment in DURABILITY II Study
April 26, 2010 06:00 ET
|
ev3 Inc.
PLYMOUTH, Minn., April 26, 2010 (GLOBE NEWSWIRE) -- ev3 Inc. (Nasdaq:EVVV) today announced the completion of patient enrollment in the DURABILITY II trial, a prospective, multi-center, single-arm...
ev3 Inc. to Report 2010 First Quarter Results and Host Conference Call on April 29, 2010
April 22, 2010 06:00 ET
|
ev3 Inc.
PLYMOUTH, Minn., April 22, 2010 (GLOBE NEWSWIRE) -- ev3 Inc. (Nasdaq:EVVV) will release its 2010 first quarter financial results on Thursday, April 29, 2010, before regular market trading hours.
The...
ev3 Inc. Announces Supply Agreement With MEDRAD, Inc. in Preparation for DEFINITIVE AR Pilot Trial
April 08, 2010 17:00 ET
|
ev3 Inc.
PLYMOUTH, Minn., April 8, 2010 (GLOBE NEWSWIRE) -- ev3 Inc. (Nasdaq:EVVV) today announced the initiation of a supply agreement with MEDRAD Interventional™/Possis®. Under terms of the...